ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2188

Parent Verses Patient Perspectives of Health-Related Quality of Life Among Children with Vasculitis

Clare Peckenpaugh1, Aimee Hersh2, Sara Stern2, Erin Treemarcki2, Peter Merkel3 and Karen James2, 1University of Utah Department of Pediatrics, Salt Lake City, UT, 2University of Utah, Salt Lake City, UT, 3University of Pennsylvania, Philadelphia, PA

Meeting: ACR Convergence 2024

Keywords: ANCA associated vasculitis, Patient reported outcomes, Pediatric rheumatology

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Pediatric Rheumatology – Clinical Poster III

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Vasculitis is a group of chronic, relapsing diseases that can lead to significant morbidity due to both disease and treatment, impacting patients’ health related quality of life (HRQoL).  Little is known about how vasculitis affects children’s HRQoL.  This study compared the perceptions of children with vasculitis to their parent’s perceptions of their child’s HRQoL.

Methods: A prospective, cross-sectional pilot study of patients with vasculitis seen in a pediatric rheumatology clinic at a tertiary care facility from 11/2021-2/2024.  Patients were eligible if they had received a diagnosis of chronic vasculitis before their 18th birthday.  Subjects and one of their parents completed Patient-Reported Outcomes Measurement Information System (PROMIS) patient and parent proxy short forms, respectively.  PROMIS measures are reported as t-scores normalized to a U.S. population to a mean of 50 and a standard deviation of 10.  Physicians scored disease activity and damage concurrently using the Pediatric Vasculitis Activity Score (PVAS) and the Pediatric Vasculitis Damage Index (PVDI).  

Results: Twenty-four patients were enrolled with 20 having both patient and parent PROMIS short forms completed.  Median age at enrollment was 14.5 (IQR 12,16) years with median age at diagnosis of 12.2 (IQR 10.3,15) years.  Patients had ANCA-associated vasculitis (n=15), Behçet’s disease (2), polyarteritis nodosa (2), or IgA vasculitis (1).  Subjects had a median PVAS score of 0 (IQR 0,3) with 7/20 with active disease defined by a PVAS of >0.  19/20 patients had at least one item of damage as scored on the PVDI, with a median score of 2.5 (IQR 1,5).  PROMIS t-scores for patients and parents are shown in Figure 1.  The median score for nearly all domains for both subject and parent responses was worse than the reference population, except for anger in the subject responses.  While the overall distributions of responses between subject and parent widely overlapped, when looking at the difference in subject-parent dyads, considerable discordance was frequently seen, with no consistent trend of parents rating their child worse than the subjects themselves (Figure 2).  Figure 3 shows the distribution of the absolute magnitude of the difference between subject-parent dyads.  In the domains of anger, anxiety, fatigue, pain, depression, peer relationships, and mobility, the 75th percentile for the magnitude of the difference was 10 or higher, demonstrating significant discordance.

Conclusion: Both patients with pediatric-onset vasculitis and their parents report reduced patient HRQoL in several physical and psychosocial domains.  However, patients and parents frequently have discordant scores relative to reference populations.  These results demonstrate the importance of capturing both the patient and parent response to gain a more complete picture of how pediatric vasculitis impacts HRQoL.  Further research could investigate the impact of age on this discordance and the variation of discordance across different vasculitides, all to help develop targeted approaches to support children with vasculitis.

Supporting image 1

Figure 1. Patient-Reported Outcome Measures Information Systems (PROMIS) T-Scores. Boxes with a solid border represent patient response; those with a dotted margin represent the parent response. A higher T-score in a domain represents more of a domain being measured; T-scores are normalized to a U.S. reference population with a mean T-score of 50, and a standard deviation of 10. Higher scores represent worse outcomes for anger, anxiety, fatigue, pain interference, sleep-related impairment, sleep-disturbance, and depressive symptoms; lower scores represent worse outcomes for cognitive function, mobility, and peer relationships.

Supporting image 2

Figure 2. Patient vs Parent-Proxy T-Scores in Patient-Reported Outcome Measures Information Systems (PROMIS) Domains. A higher T-score in a domain represents more of the domain being measured. Higher scores represent worse outcomes for anger, anxiety, fatigue, pain interference, sleep-related impairment, sleep-disturbance, and depressive symptoms; lower scores represent worse outcomes for cognitive function, mobility, and peer relationships. Each dot represents a patient-parent dyad. The upper right and lower left quadrants represent areas where the patient and parent responses are concordant( i.e. both rank the patient as better or worse than the reference population.

Supporting image 3

Figure 3. The Absolute Value of the Difference in Subject vs Parent-Proxy T-Scores in Patient-Reported Outcome Measures Information Systems (PROMIS) Domains.


Disclosures: C. Peckenpaugh: None; A. Hersh: None; S. Stern: None; E. Treemarcki: None; P. Merkel: AbbVie/Abbott, 2, 5, Amgen, 2, 5, argenx, 2, AstraZeneca, 2, 5, Boehringer Ingelheim, 3, 5, Bristol Myers Squibb, 2, 5, Cabaletta, 2, ChemoCentryx, 2, 5, CSL Behring, 2, Dynacure, 2, Eicos, 5, Electra, 5, EMDSerano, 2, Forbius, 2, 5, Genentech/Roche, 2, 5, Genzyme/Sanofi, 2, 5, GSK, 2, 5, HiBio, 2, Immagene, 2, InflaRx, 2, 5, Jannsen, 2, Kiniksa, 2, Kyverna, 2, Magenta, 2, MiroBio, 2, Neutrolis, 2, Novartis, 2, NS Pharma, 2, Pfizer, 2, Q32, 2, 11, Regeneron, 2, Sanofi, 5, Sparrow, 2, 11, Takeda, 2, 5, Talaris, 2, UpToDate, 9, Visterra, 2; K. James: None.

To cite this abstract in AMA style:

Peckenpaugh C, Hersh A, Stern S, Treemarcki E, Merkel P, James K. Parent Verses Patient Perspectives of Health-Related Quality of Life Among Children with Vasculitis [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/parent-verses-patient-perspectives-of-health-related-quality-of-life-among-children-with-vasculitis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/parent-verses-patient-perspectives-of-health-related-quality-of-life-among-children-with-vasculitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology